Table 2

Summary of reports of HSCT for CIDP

nAge at onsetGenderDisease duration
ConditioningClinical outcomeDuration of follow-up
(months after HSCT)
Vermeulen et al 31 78 138M120BEAMGood recovery, but still on prednisone 5 mg/day and relapse after 5 years>6060
Kamat et al 82 242M24Cy+ATGUnable to walk to ambulant18None
Oyama et al 79 132F30Cy+ATGRankin functional score from 4 to 122None
Barreira et al 81 124M144Cy+ATGShort transient response21
Mahdi-Rogers et al 80 329F252Cy+ATGMRC sum score 39–48–292618
58F156Cy+ATGMRC sum score 58–626None
72M72Cy+ATGMRC sum score 46–3419None
Axelson et al 84 156M11CyINCAT score from 10 to 210125
36Cy+ATGINCAT score from 6 to 2None
Press et al 83 1116–6710 M, 1 F11–228CY+ATG (7)Median INCAT score from 6 to 16–10123
BEAM (3)14
Melphalan (1)14
Bregante et al 85 124M7Thiotepa+Cy+G-CSFWheelchair users to ambulant for 6 months to unable to walk606
Fludarabin+Cy+TBI*Unable to walk to ambulantNone
  • *Allogeneic HSCT.

  • ATG, antithymocyte globulin; CIDP, chronic idiopathic demyelinating polyneuropathy; HSCT, haematopoietic stem cell transplantation; TBI, total body irradiation; BEAM, the combination of  carmustine (BCNU), etoposide, cytarabine (Ara-c), and melphalan; Cy, cyclophosphamide; G-CSF, granulocyte colony stimulating factor; MRC, Medical Research Council Scale for Muscle Strength; INCAT, ’Inflammatory Neuropathy Cause and Treatment Scale.